Kenvue Ties Feminine-Care Sales And Bond Covenant Removal To Kimberly-Clark Deal Closing
Kenvue's quarterly report now cites regulator-driven divestitures and a $7 billion note exchange, all contingent on the merger.
Kenvue, the maker of Tylenol, Neutrogena and Listerine, has signed agreements to sell its feminine care business in certain countries to win regulatory approval for its merger with Kimberly-Clark, its third-quarter 10-Q shows. The report no longer carries the line from the prior quarter saying the deal was expected to close in the fourth quarter.
Brazil brands go to Essity
The divestitures include Brazil's Carefree, Sempre Livre and o.b. tampon brands, which go to Essity Aktiebolag. The 10-Q says the sales depend on completion of the Kimberly-Clark deal and, for some, on outstanding approval in the respective country.
The second-quarter filing had said the merger was expected to close in the fourth quarter of 2026 and pointed to foreign regulatory approvals. The new report drops that timing language.
Bond covenants set to disappear
Kimberly-Clark began offers on September 28 to swap Kenvue's Senior Notes for up to $7,000,000,000 of new Kimberly-Clark notes and cash, and asked noteholders to consent to stripping substantially all restrictive covenants. Kenvue signed a supplemental indenture on October 9 making those changes, but they take effect for a series only when its exchange settles.
The offers hinge on the merger closing, and they should lapse around that closing date. The Senior Notes carry an estimated fair value of $6.5 billion, against $6.9 billion in book value. Total debt was $8,206 million at quarter-end.
The business and the quarter
Kenvue reports three segments: Self Care, Skin Health and Beauty, and Essential Health. Third-quarter net sales rose 3.2% to $3.9 billion and net income rose to $430 million from $398 million.
The tax provision rose to $179 million from $128 million, and the effective rate was 29.4% against 24.3% a year earlier. The company cited fewer favorable return-to-provision adjustments, a shift in where income was earned, and a partial offset from a release of tax reserves after favorable audits.
Dividends payable stood at $404 million at quarter-end, against none at year-end 2025, as the 21-cent dividend was declared before its October 2 payment.
Deal terms and the next date
Under the November 2025 agreement, Kenvue shareholders get 0.14625 Kimberly-Clark shares plus $3.50 in cash per share, and are expected to own about 46% of the combined company. Kenvue, which will not give forward guidance because of the pending deal, had a market value of $37.6 billion at the original report's time.
Kimberly-Clark's exchange offers for Kenvue notes are set to expire at 5:00 p.m. New York time on November 2, 2026, unless extended again, per its announcement.
The notes only change hands, and the covenants only fall away, if the merger closes.
Sources
- 10-Q Filing — Kenvue Inc. (KVUE) — SEC EDGAR
- 10-Q Filing — Kenvue Inc. (KVUE), Q2 FY2026 filed 2026-08-06 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, q326earningspressrelease.htm) — Kenvue Inc., filed 2026-10-30 — SEC EDGAR
- Kenvue: Q3 Earnings Snapshot — Associated Press
- Kenvue's Q3 Earnings on the Horizon: Key Insights for Investors — Yahoo Finance
- Kimberly-Clark Corporation Announces Extension of the Expiration Date for Exchange Offers for Kenvue Notes – Company Announcement - FT.com — Financial Times
- Kenvue Non-GAAP EPS of $0.29 in-line, revenue of $3.89B beats by $30M (KVUE:NYSE) — seekingalpha.com
- Kenvue: Q3 Earnings Snapshot – WTOP News — wtop.com